

How do the activities of daily living decline in people living with rarer dementias? A systematic review.

Beatrice Taylor^{*1}, Suraya Mohamud², Emilie V Brotherhood², Emma Harding², Claire Waddington², Paul M Camic², Daniel C Alexander¹, Sebastian J Crutch², Joshua Stott³, Chris Hardy^{**2}, Neil P Oxtoby^{**2}

1. Centre for Medical Image Computing, Departments of Computer Science and Medical Physics, University College London, London, UK
2. Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, UK
3. Adapt Lab, Research department of Clinical, Educational and Health Psychology, University College London, London, UK

** Chris Hardy and Neil P Oxtoby were co-senior authors.

* Correspondence to:

Beatrice Taylor

The Centre for Medical image Computing, 90 High Holborn, Floor 1, London, WC1V 6LJ

Email: beatrice.taylor.20@ucl.ac.uk

Abstract

Objective To study how activities of daily living (ADLs) decline over the progressive course of rarer dementias (prevalence below 10%), in a systematic review of the literature.

Methods Relevant studies were identified by searching Medline, Embase, Emcare, PsycINFO and Cinahl. The databases were searched for terms relating to (rarer dementias) AND (activities of daily living) AND (longitudinal OR cross-sectional studies), using a pre-established protocol registered with the international prospective register of systematic reviews (registration: CRD42021283302).

Results A total of 579 articles were screened for relevant content, of which 20 full-text publications were included in the analysis. Nineteen studies were about rarer dementias on the frontotemporal dementia/primary progressive aphasia spectrum, and one was about posterior cortical atrophy. Long term description of decline was limited to just seven studies following patients for longer than five years. The rate of decline, sequence of symptom onset, and symptom duration were also highlighted.

Conclusion Descriptions of ADL progression were inadequately long term, covering an average of 3.5 years from symptom onset, and lacked phenotypic specificity. The literature disproportionately studied dementias on the frontotemporal dementia spectrum. To facilitate better care, more longitudinal data, quantitative analyses, and development of rarer dementia-specific ADL scales is needed. Given the low prevalence of rarer dementias, big data analyses may never be applicable and so personalised medicine approaches should be pursued, including innovative possibilities in digital biomarkers such as from wearable technology.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Introduction

Dementia is a clinical syndrome of progressive cognitive decline with impaired social or occupational functioning. There are currently over 850,000 people living with dementia (PLWD) in the UK alone¹. Of the major neurodegenerative dementias, the most common form is typical Alzheimer's disease (tAD), which is estimated to account for 50-75% of dementia diagnoses in the UK¹. Typical Alzheimer's disease is sporadic, has an older age of onset of symptoms (>65 years) and is characterised by episodic memory loss.

This review considers low prevalence dementias which are estimated to account for less than 10% of total dementia diagnoses in the UK. These 'rarer dementias' are often characterised by progressive difficulties with cognitive symptoms other than memory and/or developing at a relatively younger age (pre-65) and/or may be an autosomal dominant disease^{2,3}. Figure 1 illustrates the rarer dementias considered in this review and their dominant pathologies.

The term 'activities of daily living' (ADL) refers to functional acts that are necessary to live independently, encompassing both 'basic activities of daily living' (BADL) such as eating, washing and continence as well as 'instrumental activities of daily living' (IADL) such as organising finances, correspondence, and cooking. For tAD, staging scales provide detailed descriptions of how these ADLs change over the course of the disease progression.

For PLWD, care needs can be complex and difficult to address, which reduces their own, and their carers', health-related quality of life. This is exacerbated by atypical symptoms^{4,5}, which are common in the rarer dementias. Many of the rarer dementias are also young onset dementias (YOD). Experiencing dementia at any age can be devastating, but in YOD there are additional concerns and care needs relating to the PLWD's age, such as work, mortgages, and young children. Furthermore, individuals with YOD often experience a delay to diagnosis which results in difficulties accessing the right care at appropriate times⁶.

Studies on carers' experiences in the rarer dementias have indicated a need for better education and understanding^{7,8}. Understanding of decline in ADLs is important, as this knowledge enables anticipation of care needs, helping carers prepare emotionally and practically for each expected symptom. Objective descriptions of decline are fundamental for evaluating novel care interventions and can be used as outcome measures in clinical trials⁹.

While there have been systematic reviews of activities of daily living in the more prevalent dementias¹⁰, there is limited systematic synthesis of research into ADLs in people with less common neurodegenerative dementias. This review seeks to understand how ADLs evolve over time, which methods have been used to quantify progression, and what the implications are for care needs in this underserved group of patients.

Longitudinal ADLs in the most common dementias

Alongside tAD, other prevalent dementias include vascular dementia and Lewy body dementia. Vascular dementia (VaD) refers to conditions of vascular brain damage and is characterised by decline in attention and executive functioning¹¹. Lewy body dementia is an umbrella term encompassing dementia with Lewy bodies (DLB) and Parkinson's disease

dementia (PDD): diseases that are pathologically defined by the presence of Lewy bodies, and associated with changes to cognition, parkinsonism, and hallucinations^{12,13}. A previous systematic review has addressed ADL decline in the more prevalent neurodegenerative dementias, concentrating on tAD, VaD and PDD¹⁰. Separate studies have addressed ADLs in DLB, finding that BADLs and IADLs are more impaired early on in DLB compared to tAD¹⁴, but over time functional changes are comparable¹⁵.

Rarer Dementias

Frontotemporal dementia, primary progressive aphasia, posterior cortical atrophy, familial Alzheimer's disease and familial frontotemporal dementia can be referred to under the collective term of rarer dementia³, which can occur concurrently in some people. A summary of the rarer dementias follows.

Frontotemporal Dementia (FTD) is an umbrella term describing clinical syndromes caused by progressive deterioration of networks centred on the frontal and temporal lobes, accounting for 2% of all dementia diagnoses in the UK¹. The term encompasses behavioural variant FTD (bvFTD)¹⁶, semantic variant primary progressive aphasia (svPPA) and non-fluent/agrammatic variant primary progressive aphasia (nfvPPA).

Primary progressive aphasia (PPA) is a partially overlapping term with FTD which refers to dementias characterised by initial changes in speech and/or language^{17,18}. It's estimated prevalence is three cases per 100,000¹⁷ (<1% of all dementia diagnoses in the UK, based on dementia prevalence of 850,000/67.22 million). The three most common variants are svPPA, nfvPPA and logopenic variant PPA (lvPPA)^{17,18}.

Posterior cortical atrophy (PCA) is a dementia characterised by changes to visuoperceptual and visuospatial processing^{19,20}. The most common pathology associated with PCA is Alzheimer's disease pathology; however, amongst all individuals with Alzheimer's disease pathology, fewer than 5% (<2.5-3.75% of all dementia diagnoses in the UK, based on prevalence estimates of tAD) present clinically with PCA²⁰.

Familial Alzheimer's Disease (fAD), and familial FTD (fFTD) are dominantly inherited forms of AD and FTD respectively, with typically younger onset^{21,22}. Whilst symptom presentation in these dementias is comparable to the sporadic variants, the fact they are dominantly inherited results in specific care needs relating to the stress of caregivers, who are often the children of patients, having a genetic susceptibility to develop the same condition²³.

Methods

Protocol and registration

The protocol for this systematic review was prepared according to PRISMA guidelines²⁴, and registered with PROSPERO (registration: CRD42021283302) prior to data extraction.

Search strategy and eligibility criteria

A search was conducted across the following five databases: Embase, Medline, Emcare, PsycINFO and Cinahl, from inception up to 7th September 2021. The search terms consisted of three blocks. The first block contained keywords related to longitudinal or cross-sectional studies, the second block contained keywords relating to activities of daily living and the third block contained keywords relating to the rarer dementias. The three blocks were combined with an AND operator.

Studies were included if they (1) were specifically about a dementia whose prevalence was estimated to account for less than 10% of UK dementia. This included: primary progressive aphasia, semantic variant PPA, logopenic variant PPA, non-fluent/agrammatic variant PPA, posterior cortical atrophy, frontotemporal dementia, behavioural variant frontotemporal dementia, familial frontotemporal dementia, familial Alzheimer's disease. (2) addressed the ADLs of the PLWD. The study had to be primarily about the person living with dementia; in cases where data came from carers the data had to primarily address the needs of the care receiver (i.e. the PLWD). IADLs and BADLs were both considered. (3) were EITHER longitudinal (i.e. reporting on the same individuals over time) OR have a cross-sectional design to examine progression across different groups (i.e. direct comparison of individuals at different disease stages). (4) had a sample size of at least five people living with a rarer dementia, analysed separately to control participants. (5) were published in English in a peer reviewed journal. Studies were excluded if they were (1) about typical Alzheimer's Disease, vascular Dementia, Lewy Body Dementia, or non-neurodegenerative Dementias.

Screening procedure

A three-step procedure was used, first screening studies by title, then by abstract then finally the full text was read and inclusion was determined based on the eligibility criteria. All stages were conducted by the primary reviewer (BT). At all three stages a random 10% of all articles were screened by an independent rater (SM). Disagreements were discussed by the reviewers (BT and SM) and resolved. The studies identified for inclusion were manually citation searched using Google Scholar in March 2022 (by BT and CH) to identify other relevant studies.

Data extraction

We used a spreadsheet to store extracted data in the following domains: author name(s), publication year, size of sample, study design, length of follow-up (if any), setting (e.g. the clinic that subjects were recruited from), diagnostic criteria, genetic testing, use of in vivo measures to confirm diagnosis (e.g. neuroimaging), confirmation of diagnosis at autopsy, measures of ADLs (including whether the measure was custom developed for the study), method of analysis (e.g. statistical assessment, linear regression), the reported sequence of ADL decline, and the rate of ADL decline.

Quality rating

A quality assessment of the included literature was undertaken independently by two reviewers (BT and CH) using a quality assessment adapted from the Joanna Briggs Institute critical appraisal tools²⁵ with additional questions to address bias specific to the topic²⁶ ,

Table 1. Appraisals according to study design are given in the supplementary materials, eTables 1-3.

Results

Selection processes

A total of 864 studies were retrieved, resulting in 579 after removing duplicates. Of these studies 33 were sought for retrieval based on title and abstract, 32 articles were retrievable and read in full by the reviewer with 14 deemed eligible for inclusion. Citation searches of the 14 initial records identified a further six articles. More details can be found in the PRISMA diagram - Figure 2.

Synthesis

We grouped studies according to the syndrome/disease under consideration. To facilitate comparison across dementia variants we use prevailing contemporary diagnostic terminology throughout (for example svPPA rather than semantic dementia — SD). eTable 4 in the supplementary materials contains the original diagnosis of participants in the studies, and the contemporary interpretation.

Table 2 shows the main characteristics and outcomes of interest for each included study. Where given in the original study, p-values were included in the table. Due to the small amount of literature the findings of all studies were reported, with results from higher-quality studies presented first — according to the quality rating in Table 1.

Study characteristics and participants

Across the 20 studies there was a total of n=3,309 participants diagnosed with a rarer dementia, some of whom may have been included in multiple studies. Of these participants, the average age at the start of the study was 67.26 years. Study countries included Australia (k=4), Brazil (k=2), France (k=2), Italy (k=1), Japan (k=1), UK (k=4) and the US (k=5). For one study the country was unclear.

Four studies were cross-sectional. Sixteen studies were longitudinal, of which 10 were case series studies and six were cohort studies. In the longitudinal studies, study duration ranged between one and eleven years, with a mean of 3.5 years. Table 3 gives a breakdown of study timeframe versus dementia variant.

Despite the literature search encompassing a broad set of rarer dementia terminology, 19 of the 20 studies focussed on PLWD with a diagnosis in the FTD/PPA spectrum. The remaining study focussed on PCA²⁷. Ten studies compared multiple rarer dementias within the FTD/PPA spectrum. As expected for low prevalence diseases small sample sizes were observed, with just three studies exceeding 100 individuals in any single dementia variant^{28–30}.

All cohorts studied were recruited through specialist cognitive disorders clinical services. Five studies were conducted using data collected from FRONTIER Frontotemporal Dementia

Group, Australia^{29,31–34}; four were based in Addenbrookes Hospital, UK^{27,35–37}; three used data collected by the National Alzheimer’s Coordinating Center (NACC), US^{28,30,38}.

All studies used clinical diagnostic criteria. Some used neuroimaging techniques to confirm diagnosis, such as magnetic resonance imaging^{31,36,37,39–42} or A β positron emission tomography^{39,42}. One study confirmed pathology at autopsy³⁸.

Eight studies used the Disability Assessment for Dementia (DAD)⁴³ to measure ADL decline. The DAD consists of 40 items, 17 addressing BADLs and 23 addressing IADLs, each of which are classified as relating to initiation, planning, or organisation. The DAD was primarily developed for assessment of functional decline in tAD⁴⁴. Some studies used custom informant questionnaires, which were tailored to specific dementia variants. One study developed and validated a new FTD rating scale (FTD-FRS)³⁷.

All but one study⁴¹ used statistical methods to describe longitudinal change. Significance tests were used to verify decline; regression was used to predict ADL decline^{30,31}. Some studies adjusted for covariates to statistically account for confounding factors^{29,30,42,45}.

There was considerable variation in description and assessment of ADL decline. Six studies only collected data at two time points, resulting in symptoms categorised as occurring by baseline, or after 12 months. The most detailed study sequentially ordered eight ADLs, based on data collected over 10 years⁴⁶. Some studies found that the rate of decline was faster in rarer dementias compared to tAD^{32,40,47}. Two studies explicitly discussed the implications of the results for addressing care needs^{27,37}. Table 3 presents a summary of each study’s relevant findings.

Results for specific diagnostic variants

bvFTD

Eight studies included people living with bvFTD^{29,30,34–37,40,48}, including one study of individuals living with frontal variant FTD (fvFTD)³⁵. Amongst the five longitudinal studies study duration was in the range of 1-6 years, with a mean of 2.4 years. Two studies identified increased appetite/overeating as an initial symptom in bvFTD^{34,35}. The sequence of ADL decline was found to be IADLs followed by BADLs⁴⁰, specifically: initiation > planning > BADLs³⁶. Ability to use the stove and to travel were found to decline significantly faster in bvFTD than in tAD, however overall rate of functional decline was comparable³⁰. The rate of functional decline was found to be faster in bvFTD compared to svPPA or nfvPPA using a single follow-up twelve months after baseline³⁷.

svPPA

Nine studies included people living with svPPA^{31,33–37,39,40,46}. Amongst the seven longitudinal studies study duration was in the range of 1-10 years, with a mean of 3 years. One study gave a particularly clear description of the sequence of ADL decline, reporting that symptoms occurred as: reading/writing > work/housework > daily activities > eating > continence > dressing⁴⁶. Another study found the first symptom of functional decline was rigid routines and

unusual food choices³⁴. Annual rate of decline in ADLs was found to be highest in planning, using a single follow-up twelve months after baseline⁴⁰.

There was conflicting evidence as to whether the rate of IADL decline was more pronounced in *nvPPA*³³ or *svPPA*³⁶. The rate of functional decline was comparable between *svPPA* and *tAD*⁴⁰.

nvPPA

Seven studies included people living with *nvPPA*^{31–33,36,37,39,40}. Amongst the six longitudinal studies study duration was in the range of 1–3.5 years, with a mean of 1.7 years. The initial symptoms of functional decline were found to be language and household chores³². There was variation as to whether decline occurred concurrently in BADLs and IADLs using a single follow-up twelve months after baseline^{32,40}, or whether decline in BADLs preceded decline in IADLs³⁶.

lvPPA

Three studies included people living with *lvPPA*^{31,32,39}. All studies were longitudinal, study duration was in the range of 1–3.5 years, with a mean of 2.3 years. This was the least represented of the three most common PPA variants, which might be expected since it is the most recently described⁴⁹. Decline in IADLs was more significant than decline in BADLs, with marked decline in planning and execution 12 months after baseline³².

PCA

One study included people living with *PCA*²⁷. This study was cross-sectional. The sequence of ADL decline was found to be impairment managing finances/correspondence and meal preparation, followed by impairment across BADLs.

Results for broader diagnostic groups

FTD

Three studies included people living with *FTD* without differentiating between variant^{38,41,47}. All studies were longitudinal, study duration was in the range of 1–6 years, with a mean of 2.7 years. Dressing and eating were found to be the best-preserved ADLs⁴¹. Annual rates of decline in ADLs found that bathing, grooming, and toileting declined significantly faster in *FTD* than *tAD*³⁸.

One study considered Pick's disease (an older diagnostic term which is broadly synonymous with *FTD*) with *n*=10 individuals having pathological confirmation, and *n*=34 showing "prominent language impairments, and subtle personality changes"⁴⁷. ADL decline was reported to be significantly faster in Pick's disease compared to *tAD*⁴⁷.

PPA

Four studies included people living with PPA without differentiating by variant^{28,42,45,48}. All studies were longitudinal, study duration was in the range of 1-11 years, with a mean of 4.75 years. One study found decline in toileting, hygiene and dressing occurred five years after onset, whilst eating and walking declined seven years after onset⁴⁵. Another study reported the sequence of ADL decline as: verbal communication > transactions > meal preparation > self-care > ambulation²⁸.

When the cohort was differentiated according to amyloid-beta status (from florbetapir PET scans), the reported sequence of ADL decline amongst individuals who were amyloid beta positive ($A\beta+$) was: communication > employment and recreation > shopping and money > travel > household care > self-care⁴². Amongst individuals who were Amyloid beta negative ($A\beta-$) 'shopping and money' declined later.

Discussion

We provide a systematic review of longitudinal change in ADLs in people diagnosed with a rarer dementia, including studies of the FTD/PPA spectrum but excluding the more common dementias of VaD and LBD which have been reviewed previously¹⁰. As might be expected, the sequences and rates of ADL decline in rarer dementias differed from observations in tAD, and differed among the rarer dementias. Reported patterns of ADL decline varied between studies within a single dementia syndrome, reflecting either study-level variation in diagnostic specificity, or genuine within-syndrome heterogeneity not captured by single studies. This suggests the need for further studies, ideally with more detailed and dementia-specific descriptions of functional decline, to better understand this intradiagnostic heterogeneity. Some commonalities between studies were observed, with most studies finding that decline in IADLs precedes decline in BADLs, and a subset of symptoms were identified which occurred early in the disease course.

These findings are different to those in the more prevalent dementias. A previous systematic review concerning tAD, VaD, and PDD found that the most affected ADLs are eating and dressing¹⁰. The review suggests this finding may be influenced by more studies focusing on the latter stages of the disease. Studies on DLB have found greater impairment in BADLs and IADLs initially compared to tAD¹⁴, but long-term functional changes are comparable¹⁵.

Of the studies included in this review there was only one outside of the FTD/PPA spectrum. This might be expected from prevalence estimates as FTD is one of the more prevalent rarer dementias, it's estimated to account for 2% of dementia diagnoses in the UK¹. Additionally, FTD/PPA findings were dominated by datasets collected from a single dementia research clinic, the FRONTIER Frontotemporal Dementia Group, Australia^{29,31-34}.

Just two of the ADL scales used in the studies were specifically developed for the dementia variants they were being used to measure. The use of non-rarer dementia specific staging scales could lead to under reporting of activities of daily living that are variant specific. Since tAD is older age of onset, staging scales developed for tAD fail to measure ADLs more relevant to younger people, meaning that age specific needs are overlooked. The only rarer dementia specific staging scales of ADL decline in the literature were the FTD-FRS and CDR-FTLD, both of which assess FTD decline. The FTD-FRS covers domains of behaviour, outings

and shopping, household chores and telephone, finances, medications, meal preparation and eating, and self-care and mobility — a comprehensive assessment of ADL. However, none of the items included specifically pertain to language, potentially limiting its utility for tracking symptom severity in the primary progressive aphasia.

There was variation across studies of the reported sequence in which ADLs declined, as well as variation in the rate of decline, which may be accounted for by diagnostic criteria. Each rarer dementia is itself an umbrella term which conceals heterogeneity in both pathology and disease presentation. The oldest study in this review was published in 1999⁴¹ — disease definitions and diagnostic criteria have evolved since then. There was a trend for recent studies to classify individuals' diagnosis more specifically, incorporating neuroimaging results and genetics, thus reducing the likelihood of misdiagnosis.

Longitudinal study duration varied between one and ten years, likely accounting for the variation in reported detail of specific symptoms of ADL decline. Long term studies which follow individuals from diagnosis to death allow for detailed descriptions on when each symptom occurs. Comparatively, studies which collect data at just 12 month follow up from baseline only provide enough information to differentiate between symptoms which occur during that year, and those that occur later. Due to the short timescale of studies, the existing literature does not appropriately nor equally represent activities of daily living in all (early, middle, and late) stages of decline.

There was very limited practical discussion of how findings could be used to support care, perhaps due in part to the insufficient coverage of all stages of decline described above. Staging scales that provide detailed descriptions of functional decline can enable carers to make legal, financial, care planning and housing decisions, thus reducing carer burden^{7,8}, and supporting independence for PLWD. Furthermore, findings could inform support groups which create networks of individuals with similar rarer diagnoses, facilitating both formal teaching, and informal peer-to-peer education.

Limitations

There are limitations to this review. In excluding studies that did not explicitly address ADL decline as a primary focus, we may have overlooked studies where ADL decline was secondary to a description of progression in terms of neuroimaging or psychosocial symptoms. This review covered a range of different dementias which limited the cross comparison of studies. Four studies were cross-sectional, and amongst the longitudinal studies follow-up time varied, precluding a meta-analysis.

Recommendations and Future Directions

To better understand ADL decline in the dementias, especially the rarer dementias, requires more longitudinal data, quantitative analyses, and development of dementia-specific ADL staging scales. Future work could employ emerging research into wearables⁵⁰ to collect longitudinal data over a wider range of ADLs specifically selected for their relevance to dementia variant, at more frequent and regular intervals. Wearables would also facilitate verification of self-reported data, which may overestimate or underestimate abilities.

Future work must address ADL decline outside of the FTD/PPA spectrum. There were no studies on autosomal-dominantly inherited dementias. fAD and fFTD are typically young onset dementias^{21,22}; as such they have additional age-related needs, including complications around employment and parenting⁸. Hence, it would be interesting to see a description of ADL decline specific to these genetic/familial forms of rarer dementias.

Furthermore, future studies need to provide more detailed and longitudinal descriptions of ADL decline across all the specific rarer dementia variants. Understanding functional decline in rarer dementias is integral for developing personalised care. The implications for how these findings could help in care could be more explicitly addressed, for example by discussing how results could be translated into useful clinical staging scales.

Staging scales for tAD, like those used in the literature to measure decline, fail to include all the symptoms relevant to each rarer form of dementia. The development of staging scales specific to rarer dementias could better account for heterogeneity and would be a useful tool in providing additional information about the expected disease course for carers and PLWD. This work could utilise computational methods, which are increasingly being used to quantify progression in dementia. The small sample sizes in rarer dementia research limits the application of machine learning, however slightly larger datasets could be combined with computational modelling techniques to gain further insight into ADL decline.

Conclusions

Our review demonstrates the need for more comprehensive and specific descriptions of longitudinal decline in activities of daily living in rarer dementias, especially outside the FTD/PPA spectrum. The lack of knowledge necessitates studies with more longitudinal follow up, and the development and application of emerging computational techniques to rigorously quantify change. There should be a clear direction on how these descriptions can be used to inform care needs, for example in developing variant specific staging scales.

Funding

This work is part of the Rare Dementia Support Impact project (The impact of multicomponent support groups for those living with rarer dementias, (ES/S010467/1)) and is funded jointly by the Economic and Social Research Council (ESRC) and the National Institute for Health Research (NIHR). ESRC is part of UK Research and Innovation. The views expressed are those of the author(s) and not necessarily those of the ESRC, UKRI, the NIHR or the Department of Health and Social Care. Rare Dementia Support is generously supported by the National Brain Appeal (<https://www.nationalbrainappeal.org/>). BT is supported by the ESRC-funded UCL, Bloomsbury and East London Doctoral Training Partnership (UBEL-DTP) (ES/P000592/1). EH is an ESRC postdoctoral research fellow (ES/W006014/1). The NIHR UCLH Biomedical Research Centre and Wellcome Trust award 221915/Z/20/Z support DCA's work in this area. SC acknowledges support from University College London Hospitals Biomedical Research Centre. JS is supported by the UCLH NIHR Biomedical Research Centre. CJDH was supported by an RNID-Dunhill Medical Trust Pauline Ashley Fellowship (grant PA23_Hardy)

and a Wellcome Institutional Strategic Support Fund Award (204841/Z/16/Z). NPO is a UKRI Future Leaders Fellow (MR/S03546X/1).

References

1. Alzheimer's Society. Alzheimer's Society's view on demography | Alzheimer's Society. Published 2020. Accessed August 24, 2022. <https://www.alzheimers.org.uk/about-us/policy-and-influencing/what-we-think/demography>
2. Harvey RJ, Roques P, Fox NC, Rossor MN. Non-Alzheimer dementias in young patients. *The British Journal of Psychiatry*. 1996;168(3):384-385. doi:10.1192/BJP.168.3.384B
3. Brotherhood E v., Stott J, Windle G, et al. Protocol for the Rare Dementia Support Impact study: RDS Impact. *Int J Geriatr Psychiatry*. 2020;35(8):833-841. doi:10.1002/gps.5253
4. Nicolaou P, Egan S, Gasson N, Kane R. Identifying needs, burden, and distress of carers of people with Frontotemporal dementia compared to Alzheimer's disease. *Dementia*. Published online 2010. doi:10.1177/1471301209354024
5. Uflacker A, Edmondson MC, Onyike CU, et al. Caregiver burden in atypical dementias: Comparing frontotemporal dementia, Creutzfeldt-Jakob disease, and Alzheimer's disease. *Int Psychogeriatr*. 2016;28(2):269-273. doi:http://dx.doi.org/10.1017/S1041610215001647
6. van Vliet D, de Vugt ME, Bakker C, et al. Time to diagnosis in young-onset dementia as compared with late-onset dementia. *Psychol Med*. 2013;43(2):423-432. doi:10.1017/S0033291712001122
7. Diehl-Schmid J, Schmidt EM, Nunnemann S, et al. Caregiver Burden and Needs in Frontotemporal Dementia. *J Geriatr Psychiatry Neurol*. Published online 2016. doi:10.1177/0891988713498467
8. Millenaar JK, Bakker C, Koopmans RTCM, Verhey FRJ, Kurz A, Vugt ME de. The care needs and experiences with the use of services of people with young-onset dementia and their caregivers: a systematic review. *Int J Geriatr Psychiatry*. 2016;31(12):1261-1276. doi:10.1002/GPS.4502
9. Galasko D, Bennett DA, Sano M, Marson D, Kaye J, Edland SD. ADCS Prevention Instrument Project: Assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. *Alzheimer Dis Assoc Disord*. 2006;20(SUPPL. 3). doi:10.1097/01.WAD.0000213873.25053.2B
10. Maresova P, Hruska J, Klimova B, Barakovic S, Krejcar O. Activities of Daily Living and Associated Costs in the Most Widespread Neurodegenerative Diseases: A Systematic Review. *Clin Interv Aging*. 2020;15:1841. doi:10.2147/CIA.S264688
11. O'Brien JT, Thomas A. Vascular dementia. *The Lancet*. 2015;386(10004):1698-1706. doi:10.1016/S0140-6736(15)00463-8
12. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies - Third report of the DLB consortium. *Neurology*. 2005;65(12):1863-1872. doi:10.1212/01.WNL.0000187889.17253.B1
13. Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM. Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. *F1000Res*. 2017;6. doi:10.12688/F1000RESEARCH.11725.1
14. Ricci M, Guidoni SV, Sepe-Monti M, et al. Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and

- Alzheimer's disease (AD). *Arch Gerontol Geriatr*. 2009;49(2):e101-e104.
doi:10.1016/J.ARCHGER.2008.10.001
15. Cipriani G, Danti S, Picchi L, Nuti A, di Fiorino M. Daily functioning and dementia. *Dement Neuropsychol*. 2020;14(2):93-102. doi:10.1590/1980-57642020DN14-020001
 16. Sivasathiseelan H, Marshall CR, Agustus JL, et al. Frontotemporal Dementia: A Clinical Review. *Semin Neurol*. 2019;39(2):251-263. doi:10.1055/S-0039-1683379
 17. Marshall CR, Hardy CJD, Volkmer A, et al. Primary progressive aphasia: a clinical approach. *J Neurol*. 2018;265(6):1474-1490. doi:10.1007/s00415-018-8762-6
 18. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011;76(11):1006.
doi:10.1212/WNL.0B013E31821103E6
 19. Benson DF, Davis RJ, Snyder BD. Posterior Cortical Atrophy. *Arch Neurol*. 1988;45(7):789-793. doi:10.1001/ARCHNEUR.1988.00520310107024
 20. Schott JM, Crutch SJ. Posterior Cortical Atrophy. *Continuum : Lifelong Learning in Neurology*. 2019;25(1):52. doi:10.1212/CON.0000000000000696
 21. Pavisic IM, Nicholas JM, O'Connor A, et al. Disease duration in autosomal dominant familial Alzheimer disease: A survival analysis. *Neurol Genet*. 2020;6(5).
doi:10.1212/NXG.0000000000000507
 22. Moore KM, Nicholas J, Grossman M, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurol*. 2020;19(2):145-156. doi:10.1016/S1474-4422(19)30394-1
 23. García-Toro M, Cruz Sánchez-Gómez M, Madrigal Zapata L, Javier Lopera F. "In the flesh": Narratives of family caregivers at risk of Early-onset Familial Alzheimer's Disease. *Dementia*. 2020;19(5):1474-1491. doi:10.1177/1471301218801501
 24. Joanna Briggs Institute. Critical appraisal tools | JBI. Published 2020. Accessed April 19, 2022. <https://jbi.global/critical-appraisal-tools>
 25. Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training. Published 2022. Accessed April 19, 2022. <https://training.cochrane.org/handbook/current>
 26. Ahmed S, Culley S, Blanco-Duque C, Hodges JR, Butler C, Mioshi E. Pronounced Impairment of Activities of Daily Living in Posterior Cortical Atrophy. *Dement Geriatr Cogn Disord*. 2020;49(1):48-55. doi:10.1159/000506125
 27. Morrow CB, Leoutsakos JMS, Onyike CU. Functional Disabilities and Psychiatric Symptoms in Primary Progressive Aphasia. *The American Journal of Geriatric Psychiatry*. Published online July 28, 2021. doi:10.1016/J.JAGP.2021.07.013
 28. Yassuda MS, Lima da Silva TB, O'Connor CM, et al. Apathy and functional disability in behavioral variant frontotemporal dementia. *Neurol Clin Pract*. 2018;8(2):120-128.
doi:10.1212/CPJ.0000000000000429
 29. Giebel CM, Knopman D, Mioshi E, Khondoker M. Distinguishing Frontotemporal Dementia From Alzheimer Disease Through Everyday Function Profiles: Trajectories of Change. *J Geriatr Psychiatry Neurol*. 2021;34(1):66-75.
doi:10.1177/0891988720901791
 30. Foxe D, Irish M, Hu A, et al. Longitudinal cognitive and functional changes in primary progressive aphasia. *J Neurol*. 2021;268(5):1951-1961. doi:10.1007/S00415-020-10382-9

31. Jang J, Cushing N, Clemson L, Hodges JR, Mioshi E. Activities of daily living in progressive non-fluent aphasia, logopenic progressive aphasia and Alzheimer's disease. *Dement Geriatr Cogn Disord*. 2012;33(5):354-360. doi:10.1159/000339670
32. O'Connor CM, Clemson L, Flanagan E, et al. The Relationship between Behavioural Changes, Cognitive Symptoms, and Functional Disability in Primary Progressive Aphasia: A Longitudinal Study. *Dement Geriatr Cogn Disord*. 2016;42(3-4):215-226. doi:10.1159/000449283
33. O'connor CM, Clemson L, Hornberger M, et al. Longitudinal change in everyday function and behavioral symptoms in frontotemporal dementia. *AAN Enterprises*. Published online 2016. Accessed December 7, 2021. <https://cp.neurology.org/content/6/5/419.short>
34. Ikeda M, Brown J, Holland AJ, Fukuhara R, Hodges JR. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. *J Neurol Neurosurg Psychiatry*. 2002;73(4):371-376. doi:10.1136/jnnp.73.4.371
35. Mioshi E, Kipps CM, Dawson FK, Mitchell RJ, Graham BA, Hodges JR. *Activities of Daily Living in Frontotemporal Dementia and Alzheimer Disease*. Vol 68.; 2007.
36. Mioshi E, Hsieh S, Savage MS, Hornberger MM, Hodges JR. *Clinical Staging and Disease Progression in Frontotemporal Dementia*.; 2010. <http://www.ftdrg.org>
37. Rascofsky K, Salmon M; DP, Lipton ; A M, et al. *Rate of Progression Differs in Frontotemporal Dementia and Alzheimer Disease*.; 2005.
38. Ferrari C, Polito C, Vannucchi S, ... IPAD&, 2019 undefined. Primary Progressive Aphasia: Natural History in an Italian Cohort. *Alzheimer Dis Assoc Disord*. Published online 2019. Accessed November 16, 2021. https://journals.lww.com/alzheimerjournal/Fulltext/2019/01000/Primary_Progressive_Aphasia__Natural_History_in_an.7.aspx
39. Mioshi E, Hodges JR. Rate of change of functional abilities in frontotemporal dementia. *Dement Geriatr Cogn Disord*. 2009;28(5):419-426. doi:10.1159/000255652
40. Pasquier F, Lebert F, Lavenu I, Guillaume B. *The Clinical Picture of Frontotemporal Dementia: Diagnosis and Follow-Up*. Vol 10.; 1999. <http://BioMedNet.com/karger>
41. Moeller S, Sridhar J, Martersteck A, et al. Functional decline in the aphasic variant of Alzheimer's disease. *Wiley Online Library*. 2021;17(10):1641-1648. doi:10.1002/alz.12331
42. Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living. *Gerontologist*. 1969;9:179-186.9.
43. Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a Functional Measure for Persons With Alzheimer's Disease: The Disability Assessment for Dementia. *The American Journal of Occupational Therapy*. 1999;53(5):471-481. doi:10.5014/AJOT.53.5.471
44. le Rhun E, Richard F, Pasquier F. *Natural History of Primary Progressive Aphasia*.; 2005. www.neurology.org
45. Kashibayashi T, Ikeda M, Komori K, et al. Transition of distinctive symptoms of semantic dementia during longitudinal clinical observation. *Dement Geriatr Cogn Disord*. 2010;29(3):224-232. doi:10.1159/000269972
46. Binetti G, Locascio JJ, Corhln S, Vonscittte JP, Growdon JH. Differences Between Pick Disease and Alzheimer Disease in Clinical Appearance and Rate of Cognitive Decline. *Arch Neurol*. 2000;57(2):225-232. doi:10.1001/ARCHNEUR.57.2.225

47. Lima-Silva TB, Mioshi E, Bahia VS, et al. Disease Progression in Frontotemporal Dementia and Alzheimer Disease: The Contribution of Staging Scales. *J Geriatr Psychiatry Neurol*. 2021;34(5):397-404. doi:10.1177/0891988720944239
48. Henry ML, Gorno-Tempini ML. The logopenic variant of primary progressive aphasia. *Curr Opin Neurol*. 2010;23(6):633. doi:10.1097/WCO.0B013E32833FB93E
49. Tiersen F, Batey P, Harrison MJC, et al. Smart Home Sensing and Monitoring in Households With Dementia: User-Centered Design Approach. *JMIR Aging* 2021;4(3):e27047 <https://aging.jmir.org/2021/3/e27047>. 2021;4(3):e27047. doi:10.2196/27047




Figure 1: Underlying pathology and subsequent diagnosis for the dementias included in this review. Individuals may have a mixture of multiple dementias.

Quality Assessment	(Ahmed et al., 2020) ²⁷	(Binetti et al., 2000) ⁴⁷	(Ferrari et al., 2019) ³⁹	(Fuxe et al., 2021) ³¹	(Giebel et al., 2021) ³⁰	(Ikeda et al., 2002) ³⁵	(Jang et al., 2012) ³²	(Kashibayashi et al., 2010) ⁴⁶	(Le Rhun et al., 2005) ⁴⁵	(Lima-Silva et al., 2021) ⁴⁸
	Were the groups similar and recruited from the same population?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	NA	NA
Was the setting described in detail?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the criteria for inclusion in the sample clearly defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were objective, standard criteria used for diagnosis?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was there clear reporting of the demographics of the participants in the study?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were confounding factors identified?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Were strategies to deal with confounding factors stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Were ADLs measured in a valid and reliable way?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the timescale (longitudinal/cross-sectional) sufficient for outcomes to occur?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was follow up complete?	NA	No	Yes	No	No	NA	Yes	No	Yes	No
Were the reasons for loss to follow up described?	NA	Yes	NA	No	Yes	NA	NA	Yes	NA	No
Were the outcomes or follow up results of cases clearly reported?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were conclusions clearly supported by the data?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the relevance and transferability evident?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was statistical analysis appropriate?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Total	13/13	14/15	14/14	13/15	14/15	13/13	14/14	11/14	13/13	13/15

Quality Assessment	(Mioshi et al., 2009) ⁴⁰	(Mioshi et al., 2010) ³⁷	(Mioshi et al., 2007) ³⁶	(Moeller et al., 2021) ⁴²	(Morrow et al., 2021) ²⁸	(O'Connor et al., 2016a) ³³	(O'Connor et al., 2016b) ³⁴	(Pasquier et al., 1999) ⁴¹	(Rascovsky et al., 2005) ³⁸	(Yassuda et al., 2018) ²⁹
	Were the groups similar and recruited from the same population?	Unclear	Yes	Yes	Yes	NA	Yes	Yes	NA	Yes
Was the setting described in detail?	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the criteria for inclusion in the sample clearly defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were objective, standard criteria used for diagnosis?	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Yes	Yes
Was there clear reporting of the demographics of the participants in the study?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were confounding factors identified?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes
Were strategies to deal with confounding factors stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes
Were ADLs measured in a valid and reliable way?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the timescale (longitudinal/cross-sectional) sufficient for outcomes to occur?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was follow up complete?	Yes	No	NA	No	No	No	No	No	No	NA
Were the reasons for loss to follow up described?	NA	No	NA	Yes	No	No	Yes	Yes	Yes	NA
Were the outcomes or follow up results of cases clearly reported?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were conclusions clearly supported by the data?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the relevance and transferability evident?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was statistical analysis appropriate?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Total	12/14	13/15	13/13	14/15	11/14	13/15	14/15	11/14	12/15	12/12

Table 1: Custom quality assessment of included studies.




Figure 2: PRISMA flow diagram of the identification of studies.

Study	Design	Participants	Diagnostic criteria	Setting	ADL measure	Analysis method	Main outcomes of interest
(Ahmed et al., 2020) ²⁷	Cross-sectional	PCA (n=29)	Clinical.	Oxford Cognitive Disorders Clinic, UK	DAD	Statistical and linear regression	In PCA, management of finances, correspondence and meal preparation were impaired first. Later in the disease course, there was comparable impairment across IADLs and BADLs. BADLs were significantly more impaired in PCA vs AD (p<0.05).
		AD (n=25)		Addenbrookes Early Onset Dementia Clinic, UK			
(Binetti et al., 2000) ⁴⁷	Cohort	PcD (n=44)	Clinical. 26 (10 PcD, 16 AD) had pathological confirmation	Memory Disorders unit- Massachusetts general hospital, US	BDS Weintraub ADL	Statistical and linear regression	Rate of decline was significantly faster in PcD than AD according to the BDS and Weintraub ADL. No PcD carers reported ADL impairments as the first symptom.
		AD (n=121)		Living in the community			
		Controls (n=60)					
(Ferrari et al., 2019) ³⁹	Case series	lvPPA (n=22 sporadic; n=1 PSEN1 mutation)	Clinical and neuroimaging.	Neurology department at Careggi hospital, Italy	Katz ADL Katz IADL	Statistical and logistic regression	Across variants, 14 people were severely dependent in BADLs 2.57 (mean) years from baseline. In the three subjects with a genetic mutation only one was impaired in BADL after two years.
		nfvPPA (n=25 sporadic; n=1 PGRN mutation)					
		svPPA (n=18 sporadic; n=1 PGRN mutation)					
	Cohort	lvPPA (n=41)			DAD		

Study	Design	Participants	Diagnostic criteria	Setting	ADL measure	Analysis method	Main outcomes of interest
(Fuxe et al., 2021) ³¹		nfvPPA (n=44) svPPA (n=62) Controls (n=60)	Clinical and neuroimaging	FRONTIER Frontotemporal Dementia Group, Australia		Statistical, mixed and hierarchal regression modelling	Annual rate of decline on DAD comparable across variants, (8.7 points for lvPPA and nfvPPA, 7.4 points for svPPA).
(Giebel et al., 2021) ³⁰	Cohort	bvFTD (n=306) AD (n=3045)	Clinical	National Alzheimer's Coordinating Center (NACC), US	FAQ	Statistical and linear mixed effects model	bvFTD significantly more impaired longitudinally than tAD (p<0.001). Rates of change over time are comparable in bvFTD and tAD, except for using the stove (p<0.01) and in travel (p<0.05) which decline faster in bvFTD.
(Ikeda et al., 2002) ³⁵	Cohort	fvFTD (n=23) SD (n=25) AD (n=43)	Clinical	Cognitive Disorders Clinic, Cambridge, UK	Custom informant questionnaire	Statistical	In SD there was first a change in food preference, followed by appetite increase and altered eating habits, then other oral behaviours and finally swallowing. In fvFTD the first symptom was altered eating habits and appetite increase.
(Jang et al., 2012) ³²	Cross-sectional	PNFA (n=16) LPA (n=19) AD (n=24)	Clinical	FRONTIER Frontotemporal Dementia Group, Australia	DAD	Statistical	All 3 groups declined in IADLs over 12 months, but only nfvPPA declined in BADLs over 12 months (p<0.05). nfvPPA and lvPPA showed decline in planning and execution at 12 months, but initiation score was unchanged.
(Kashibayashi et al., 2010) ⁴⁶	Case series	svPPA (n=19)	Clinical	Higher Brain Function Clinic, Ehime, Japan	Custom informant questionnaire	Statistical	Described onset period, sequence and duration of a range of ADLs. ADL decline occurred as follows:

Study	Design	Participants	Diagnostic criteria	Setting	ADL measure	Analysis method	Main outcomes of interest
							reading/writing, efficiency of work/housework, daily activities, eating, continence, dressing. 14 patients showed a decline in ADLs after an average 5.4 years from onset. After 5 years from onset some patients required specialised care for eating disturbances, dressing impairments and incontinence.
(Le Rhun et al., 2005) ⁴⁵	Case series	PPA (n=49)	Clinical	Lille Memory Centre, France	Custom informant questionnaire	Statistical	Half the patients required assistance in toileting, hygiene or dressing after 5 years from onset. Half required help eating and walking 7-8 years from onset.
(Lima-Silva et al., 2021) ⁴⁸	Cohort	bvFTD (n=31)	Clinical	Cognitive and Behavioral Neurology Group, University of Sao Paulo; Cognitive and Behavioral Neurology Group, Federal University of Minas Gerais; Department of Neurology, State University of Campinas	FTD-FRS CDR-FTLD CDR	Statistical	Higher decline at 12 month follow-up in bvFTD and PPA, than in AD. The FTD-FRS did not detect significant decline in PPA (p=0.69). The CDR was less sensitive to severe disease stages.
		PPA (n=12)					
		AD (n=27)					

Study	Design	Participants	Diagnostic criteria	Setting	ADL measure	Analysis method	Main outcomes of interest
(Mioshi et al., 2009) ⁴⁰	Case series	bvFTD phenocopy (n=10)	Clinical and neuroimaging. Phenocopy classified as lack of atrophy on MRI at baseline and follow-up.	Unclear	DAD	Statistical	There was no significant change amongst those with non-pathological bvFTD. In the pathologically verified bvFTD cases they found similar decline across initiation, planning and execution at 12 month follow up. SD and PNFA declined in planning at 12 months, whilst PNFA additionally declined in initiation.
		bvFTD pathology (n=6)					
		SD (n=11)					
		PNFA (n=9)					
(Mioshi et al., 2010) ³⁷	Cohort	bvFTD (n=57)	Clinical and neuroimaging	Cambridge, UK	FRS CDR	Statistical	Investigation of the validity of the FRS in recording longitudinal ADL decline. Found that all variants had significant decline on FRS (p<0.005) at 12 months. Individuals with bvFTD had greater functional loss than those with SD or PNFA.
		PNFA (n=41)					
		SD (n=54)					
		Controls (n=20)					
(Mioshi et al., 2007) ³⁶	Cross-Sectional	PNFA (n=10)	Clinical and neuroimaging	Addenbrookes Hospital Early Onset Dementia Clinic, UK	DAD CDR	Statistical	PNFA saw little decline on BADLs at 12 months. Impairment was worst in language related IADLs such as using the telephone and managing finance/correspondence. SD group more globally affected on IADLs than PNFA. Most SD were independent, some had specific issues choosing weather appropriate clothing. Outings and leisure/house chores were mildly impaired.
		SD (n=15)					
		bvFTD (n=15)					
		AD (n=19)					

Study	Design	Participants	Diagnostic criteria	Setting	ADL measure	Analysis method	Main outcomes of interest
							The bvFTD group was most impaired across BADLs and IADLs. Continence, dressing, eating, and hygiene were impaired. Management of finances/correspondence and outings were the worst affected IADLs.
(Moeller et al., 2021) ⁴²	Cohort	PPA A β - (n=11) PPA A β + (n=17)	Clinical and Pathological	Mesulam Center for Cognitive Neurology and Alzheimer's Disease, US	ADLQ	Statistical and linear mixed effects model	Found a difference between proteinopathies- The PPA A β + group were worse at baseline and declined faster on the ADLQ. There is no symptom sequence explicitly described but it can be inferred from the results that PPA A β + saw declined as follows: communication, employment and recreation, shopping and money, travel, household care and finally self-care. The PPA A β - was largely similar with decline in: communication, employment and recreation, travel, household care, shopping and money, and self-care.
(Morrow et al., 2021) ²⁸	Case series	PPA (n=1944). 18% were nfvPPA, 12% were SD, remainder	Clinical	National Alzheimer's Coordinating Center (NACC), US	FAQ NACC FTLD CDR	Statistical	The order of functional decline was: verbal communication, transactions, meal preparation, self-care and ambulation.

Study	Design	Participants	Diagnostic criteria	Setting	ADL measure	Analysis method	Main outcomes of interest
		were not designated a variant. Results were not split by variant.					
(O'Connor et al., 2016a) ³³	Case series	svPPA (n=18) nfvPPA (n=11)	Clinical	FRONTIER Frontotemporal Dementia Group , Australia	DAD	Statistical and linear regression	The nfvPPA group saw greater decline in IADLs at the 12 month follow up. Discusses how research could be utilised by clinicians and paid carers to prolong time until onset of functional impairment.
(O'Connor et al., 2016b) ³⁴	Cohort	bvFTD (n=21) SD (n=18)	Clinical	FRONTIER Frontotemporal Dementia Group , Australia	DAD	Statistical	First ADL decline in bvFTD was overeating, whereas in SD it was rigid routines and bizarre food choices.
(Pasquier et al., 1999) ⁴¹	Case series	FTD (n=74)	Clinical and neuroimaging	Lille Memory Clinic, France	Weintraub ADL	No statistical analysis	After two years sample had a median 10% loss of autonomy. In the final stages eating and dressing were best preserved activities.
(Rascovsky et al., 2005) ³⁸	Cohort	FTD (n=70) AD (n=70)	Clinical and autopsy confirmation	National Alzheimer's Coordinating Center (NACC), US	Custom informant questionnaire	Statistical	FTD exhibited faster decline in BADLs. FTD lost capacity for bathing, dressing, grooming and toileting (p<0.01) faster than in AD.
(Yassuda et al., 2018) ²⁹	Cross-sectional	bvFTD (n=109)	Clinical and neuroimaging	FRONTIER Frontotemporal Dementia Group , Australia;	DAD	Statistical and linear regression	Cross-sectionally compared groups according to DAD, but no results on rate or sequence of ADL decline.

Study	Design	Participants	Diagnostic criteria	Setting	ADL measure	Analysis method	Main outcomes of interest
				Cognitive and Behavioral Neurology Group, University of Sao Paulo; Cognitive and Behavioral Neurology Group, Federal University of Minas Gerais; Department of Neurology, State University of Campinas Brazil, Cognitive and Behavioral; Addenbrookes Early onset dementia clinic, UK; Nizam's Institute of Medical Sciences, India			

Table 2: Main outcomes of interest for the 20 studies included in the review.

PCA, Posterior Cortical Atrophy; AD, Alzheimer's Disease; Pcd, Pick's Disease; PPA, Primary Progressive Aphasia; PPA A β -, Amyloid beta negative PPA; PPA A β +, Amyloid beta positive PPA; lvPPA, logopenic variant PPA; nfvPPA, non-fluent/agrammatic variant PPA; PNFA, progressive non-fluent aphasia; svPPA, semantic variant PPA; SD, semantic dementia; FTD, Frontotemporal Dementia; bvFTD, behavioural variant FTD; fvFTD, frontal variant FTD, PSEN1, presenilin-1; PGRN, progranulin.

DAD, Disability Assessment for Dementia; BDS, Blessed Dementia Scale; Weintraub ADL, Weintraub Activities of Daily Living Scale; Katz ADL, The Katz Index of Independence in Activities of Daily Living; IADL, Instrumental Activities of Daily Living Scale; FAQ, Functional Activities Questionnaire.

Table 3: Distribution of studies by PLWD diagnosis versus timeframe of study. Colours indicate what domain of ADL was considered: BADL only, blue; IADL only, green; BADLs and IADLs, red.

Observation period	Rarer dementia								
	fFTD	fAD	PCA	FTD	bvFTD	PPA	svPPA	lvPPA	nvPPA
Cross-sectional			27 ●		35 ●, 29 ●, 36 ●		35 ●, 36 ●		36 ●
1 year				47 ●	48 ●, 40 ●, 37 ●	48 ●	40 ●, 37 ●, 33 ●	32 ●	40 ●, 37 ●, 32 ●, 33 ●
1-3 years				38 ●		42 ●	39 ●	39 ●	39 ●
3-5 years					34 ●	28 ●	31 ●, 34 ●	31 ●	31 ●
5-7 years				41 ●	30 ●				
> 7 years						45 ●	46 ●		